Status:
UNKNOWN
Effects of Barley Green in Patients With Hyperuricemia
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborating Sponsors:
Jinhua Municipal Central Hospital
Quzhou Kecheng People's Hospital
Conditions:
Dietary Supplement
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This experiment evaluates the effect of Barley Green in patients with hyperuricemia ， and explores the effect of Barley Green on metabolic indexes such as uric acid, blood lipids, blood glucose, free ...
Eligibility Criteria
Inclusion
- Age 18-65 years old those who are willing to accept assessment and sign informed consent.
- Under the normal purine diet, two fasting blood uric acid levels on different days: 420umol/l \<blood uric acid \<540 umol/l (male), 360 umol/l \<blood uric acid \<540 umol/l (female)
Exclusion
- Patients currently receiving treatment for hyperuricemia；
- Suffering from diseases that affect the digestion and absorption(such as chronic diarrhea, constipation, severe gastrointestinal inflammation, active gastrointestinal ulcers, after gastrointestinal resection, cholecystitis/cholecystectomy, etc.)；
- Suffering from cardiovascular and cerebrovascular diseases, grade 3 hypertension, chronic hepatitis, malignant tumors, anemia, mental illness and memory disorders, epilepsy and other diseases;
- At the same time receive other functional food nutrition support (plant active substances, health food);
- Patients with abnormal liver function (alanine aminotransferase or/and aspartate aminotransferase exceeds 3 times the upper limit of normal value); patients with abnormal renal function (serum creatinine exceeds the upper limit of normal value)；
- Suffering from infectious diseases such as active tuberculosis and AIDS;
- People who are severely allergic to the ingredients of research；
- During pregnancy or lactation;
- Patients with physical disabilities and clinicians think it is not suitable to participate in the study (for example, suffering from serious diseases not included in the discharge criteria)；
- Gouty arthritis attack ≥ 2 times;
- One episode of gouty arthritis with blood uric acid \>480 umol/l, or any of the following: age \<40 years old, evidence of gout stone or urate deposition in the joint cavity, uric acid nephrolithiasis or renal impairment (GFR≤89ml/(min·1.73m2)), hypertension, impaired glucose tolerance or diabetes, dyslipidemia, obesity, coronary heart disease, stroke, cardiac insufficiency;
- Blood uric acid\>480 umol/l combined with any of the following: uric acid nephrolithiasis or renal impairment (GFR≤89ml/(min·1.73m2)), hypertension, impaired glucose tolerance or diabetes, dyslipidemia, obesity, Coronary heart disease, stroke, heart failure.
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04438486
Start Date
April 1 2020
End Date
July 1 2022
Last Update
August 11 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310009
2
Zhejiang cancer hospital
Hangzhou, Zhejiang, China, 310022
3
Jinhua municipal central hospital
Jinhua, Zhejiang, China, 321000
4
Quzhou Kecheng People's Hospital
Quzhou, Zhejiang, China, 324000